Education
About Us
Working with TipRanks
Follow Us
Ginkgo Bioworks Holdings (DNA)
NYSE:DNA
DNA Stock Chart & Stats
$9.55
-$0.35(-3.13%)
At close: 4:00 PM EST
$9.55
-$0.35(-3.13%)
Day’s Range― - ―
52-Week Range$5.00 - $17.58
Previous CloseN/A
Volume618.97K
Average Volume (3M)914.70K
Market Cap
$578.64M
Enterprise Value$763.34M
Total Cash (Recent Filing)$461.86M
Total Debt (Recent Filing)$422.87M
Price to Earnings (P/E)―
Beta2.83
Next Earnings
Mar 04, 2026EPS Estimate
-1.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding48,523,594
10 Day Avg. Volume898,788
30 Day Avg. Volume914,703
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.71
Price to Sales (P/S)2.24
P/FCF Ratio-1.33
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue4.23
Enterprise Value/Gross Profit5.81
Enterprise Value/Ebitda-2.35
Forecast
1Y Price Target
$12.00Price Target Upside25.65% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)-4.48
Revenue Forecast (FY)$179.30M
Bulls Say, Bears Say
Bulls Say
AI Tools And Automation ExpansionExpanded AI tools and automation offerings can drive new service revenue and improve operational efficiency as client adoption grows.
Guidance ReiterationCompany reiterated guidance for Cell Engineering and Biosecurity, reinforcing revenue visibility for those core segments.
Revenue DiversificationDiversified revenue exposure and an opportunistic growth strategy reduce dependence on any single sector, improving resilience to industry swings.
Bears Say
Analyst Sentiment And Valuation PressureAnalyst price-target reductions and a valuation multiple below peers reflect weak investor sentiment and sensitivity to macro and pharma sector headwinds.
Profitability And Cash BurnA larger-than-expected adjusted EBITDA loss raises concerns about cash burn and the potential need for additional capital.
Program Activity DeclineA decline in active program count points to slowing client engagement and may pressure future revenue growth.
Ginkgo Bioworks Holdings News
DNA FAQ
What was Ginkgo Bioworks Holdings’s price range in the past 12 months?
Ginkgo Bioworks Holdings lowest stock price was $5.00 and its highest was $17.58 in the past 12 months.
What is Ginkgo Bioworks Holdings’s market cap?
Ginkgo Bioworks Holdings’s market cap is $578.64M.
When is Ginkgo Bioworks Holdings’s upcoming earnings report date?
Ginkgo Bioworks Holdings’s upcoming earnings report date is Mar 04, 2026 which is in 45 days.
How were Ginkgo Bioworks Holdings’s earnings last quarter?
Ginkgo Bioworks Holdings released its earnings results on Nov 06, 2025. The company reported -$1.45 earnings per share for the quarter, missing the consensus estimate of -$1.241 by -$0.209.
Is Ginkgo Bioworks Holdings overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings pay dividends?
Ginkgo Bioworks Holdings does not currently pay dividends.
What is Ginkgo Bioworks Holdings’s EPS estimate?
Ginkgo Bioworks Holdings’s EPS estimate is -1.46.
How many shares outstanding does Ginkgo Bioworks Holdings have?
Ginkgo Bioworks Holdings has 48,523,594 shares outstanding.
What happened to Ginkgo Bioworks Holdings’s price movement after its last earnings report?
Ginkgo Bioworks Holdings reported an EPS of -$1.45 in its last earnings report, missing expectations of -$1.241. Following the earnings report the stock price went down -20.796%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings?
Currently, no hedge funds are holding shares in DNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ginkgo Bioworks Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$12.00 (25.65% Upside)
$12.00 (25.65% Upside)
Blogger Sentiment
Neutral
DNA Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.37%
12-Months-Change
Fundamentals
Return on Equity
-50.02%
Trailing 12-Months
Asset Growth
-19.70%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
DNA Company Deck
DNA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in cost reductions and cash position, as well as strategic expansions and partnerships. However, these were offset by notable challenges in revenue declines and increased operating losses in the Cell Engineering segment. While the company is making strategic moves to position itself for future growth, the current financial metrics present a mixed picture.View all DNA earnings summariesDNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
DNA Stock 12 Month Forecast
Average Price Target
$12.00
▲(25.65% Upside)
Technical Analysis
Niagen Bioscience
―
Monopar Therapeutics Inc
―
Lyell Immunopharma
―
Jade Biosciences
―
AbSci
―
Ownership Overview
0.99% Insiders
16.42% Mutual Funds
2.25% Other Institutional Investors
65.54% Public Companies and Individual Investors